AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Kalkine | Healius Limited (ASX:HLS) Slides Sharply Amid Revenue Concerns and Broader ASX 200 Movements
May 29, 2025 04:11 PM AEST| By Team Kalkine MediaHighlights,Healius Limited (ASX:HLS) declines amid ongoing revenue contraction and weak sentiment,Industry comparisons highlight pressure on valuation within the healthcare segment,ASX 200 benchmark shows mixed movements driven by varying sectoral pe...
Emyria’s (ASX:EMD) Breakthrough PTSD Results and ANU Partnership Highlight Innovation in Mental Health Care
May 29, 2025 03:55 PM AEST| By Team Kalkine MediaHighlights,63% of PTSD patients showed no further diagnosis criteria,Emyria partners with ANU to develop mental health care models,Strong positioning in innovative ASX300 healthcare space,Emyria (ASX:EMD), a clinical-stage biotech company, has shared...
Noxopharm's HERACLES Trial Receives Green Light, Boosting Momentum Within ASX300
May 29, 2025 03:42 PM AEST| By Team Kalkine MediaHighlights,HERACLES trial approved for SOF-SKN™ in Australia,Strategic focus on chronic inflammatory conditions,Operational setup begins with expert clinical team,Noxopharm Limited (ASX:NOX) has achieved a major milestone with the approval of its HER...
ASX 200 Healthcare Spotlight: RMD Shares Trade Below Historical Multiples
May 29, 2025 03:08 PM AEST| By Team Kalkine MediaHighlights,ResMed CDI (ASX:RMD) operates within the healthcare sector and maintains a dual listing on the ASX and NYSE,RMD shares reflect a lower price-to-sales ratio compared to historical averages, supported by revenue growth,The company provides C...
Invion’s INV043 Shows Promise in Skin Cancer Treatment as ASX200 Health Innovation Gains Momentum
May 29, 2025 02:51 PM AEST| By Team Kalkine MediaHighlights,INV043 shows no adverse events in Phase I/II NMSC trial,Treatment highlights diagnostic potential through fluorescence,Phase II to refine treatment strategy with adjusted dosage,Australian biotech company Invion (ASX:IVX) has shared encour...
EBOS Dips on Major Share Sale News – What It Means for the ASX200
May 29, 2025 02:40 PM AEST| By Team Kalkine MediaHighlights,EBOS shares fall after major shareholder divests stake,$881 million share block hits market sentiment,Stock remains part of ASX dividend stocks list,Shares of healthcare and pharmaceutical distributor,EBOS Group,(ASX:EBO) dropped sharply f...
Clarity Pharmaceuticals (ASX:CU6) Progresses AMPLIFY Trial with First Patient Imaging, Boosting Prospects in ASX200
May 29, 2025 12:29 PM AEST| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals (CU6) advances phase three trial for prostate cancer diagnosis,First patient imaged in AMPLIFY trial soon after study launch,Potential breakthrough in early detection of recurrent prostate cancer,Shares of Clarity P...
Kalkine: Imugene (ASX:IMU) Schedules Key EGM to Decide on Share Consolidation and Capital Raise
May 27, 2025 03:22 PM AEST| By Team Kalkine MediaHighlights,Imugene (IMU) to host EGM on 26 June 2025,Shareholders to vote on consolidation and capital raising,Funds aimed at advancing key clinical programs,Imugene (ASX:IMU), a biotechnology company focused on innovative cancer immunotherapies, has...
Kalkine: Neuren Pharmaceuticals Delivers Strong Growth and Expansion Plans Amid ASX200 Momentum
May 27, 2025 03:13 PM AEST| By Team Kalkine MediaHighlights,Neuren posts A$166 million record income,DAYBUE drives global expansion outlook,Promising clinical trials support future pipeline,Neuren Pharmaceuticals (ASX:NEU) has made headlines with a remarkable financial performance for the year 2024...
Kalkine: PainChek Expands US Presence with Eldermark Partnership, Eyes Growth Ahead of ASX200 Inclusion
May 27, 2025 01:22 PM AEST| By Team Kalkine MediaHighlights,PainChek,teams up with,Eldermark,to grow US market reach,Integration to deliver AI-driven pain assessments in real-time,FDA clearance to unlock full-scale sales rollout,PainChek (ASX:PCK),has entered a strategic partnership with Eldermark...
Kalkine: Prescient Therapeutics (ASX:PTX) Advances Rare Blood Cancer Treatment with Phase 2a Trial Amid ASX200 Momentum
May 27, 2025 12:42 PM AEST| By Team Kalkine MediaHighlights:,Phase 2a study initiated for PTX-100 in rare Cutaneous T-Cell Lymphoma,Trial spans Australia, US, and Europe with up to 40 patients,PTX-100 targets unmet need in relapsed or refractory CTCL,Prescient Therapeutics (ASX:PTX) has reached a s...
ASX 200 Healthcare Giants: Performance Snapshot of CSL, SIG, PME, RMD, and FPH
May 26, 2025 05:26 PM AEST| By Team Kalkine MediaHighlights,CSL (ASX:CSL) shows modest gains while maintaining its leadership in biopharmaceuticals,SIG (ASX:SIG) continues to lead pharmacy distribution despite a slight decline,PME (ASX:PME) and RMD (ASX:RMD) experience minor pullbacks amid strong a...
Healthscope’s Future in the ASX300: No Taxpayer Bailout, Government Confirms
May 26, 2025 03:34 PM AEST| By Team Kalkine MediaHighlights,Government will not provide taxpayer bailout to Healthscope.,Patient care and hospital integrity remain top priorities.,Focus on orderly sale to protect all stakeholders.,The Australian Government has made it clear that Healthscope (ASX:HS...
ASX 200 Healthcare Shock: ASX:CBA Supports Healthscope Amid Receivership
May 26, 2025 02:49 PM AEST| By Team Kalkine MediaHighlights,Healthscope enters voluntary receivership amid severe financial strain and debt concerns,Commonwealth Bank of Australia (ASX:CBA) offers financial support to maintain hospital operations,Landlords issue breach notices as tenancy defaults e...
Recce Pharmaceuticals (ASX:RCE) Strengthens Patent Portfolio with Chinese Approval, Boosting Presence in ASX200 Pharma Sector
May 26, 2025 12:57 PM AEST| By Team Kalkine MediaHighlights,Recce secures patent approval in China for key anti-infective drug candidates.,Patent covers multiple bacterial and viral infections with varied administration methods.,Expansion enhances Recce’s global intellectual property footprint in m...
Which Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?
May 23, 2025 06:18 PM AEST| By Team Kalkine MediaWhich Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?
ASX 200 Health Stocks Climb Amid Capital Raisings and Diagnostic Advancements
May 23, 2025 04:31 PM AEST| By Team Kalkine MediaHighlights:,Multiple ASX-listed healthcare firms initiate capital raisings to strengthen cash positions,EMVision showcases improved stroke diagnostic performance using AI at major health conference,Monash IVF updates FY25 outlook following operationa...
Mayne Pharma (ASX:MYX) Shares Show Partial Rebound Amid Takeover Uncertainty and ASX200 Volatility
May 23, 2025 02:41 PM AEST| By Team Kalkine MediaHighlights,Mayne Pharma shares recover after sharp weekly decline,FDA concerns impact takeover negotiations with US firm Cosette,Market watchers eye implications for ASX dividend stocks and ASX200,Mayne Pharma (ASX:MYX) shares experienced a partial r...
Hengrui’s Soaring Hong Kong Debut Sparks Optimism Across ASX200 and Global Pharma Markets
May 23, 2025 12:27 PM AEST| By Team Kalkine MediaHighlights,Hengrui jumps 29% in Hong Kong listing,$2 billion capital to fuel drug innovation,Market buzz adds momentum to ASX200,In a remarkable debut that has stirred enthusiasm among global investors,,Jiangsu Hengrui Pharmaceuticals (HKG:600276),,...
Nyrada’s Breakthrough TRPC Blocker Gains Momentum in ASX200 Medical Research Space
May 23, 2025 12:00 AM AEST| By Team Kalkine MediaHighlights,Drug shows promise for stroke, heart attack, and brain injury,Early trial data confirms safety and strong tissue preservation,Anti-arrhythmic effects observed in follow-up studies,Nyrada Inc. (ASX:NYR) has reported encouraging progress on...
Advertise your brand on Kalkine Media